3004 - Safety and Efficacy of Neoadjuvant Chemoradiotherapy with Concurrent Weekly Versus Tri-Weekly Cisplatin/Nab-Paclitaxel in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

X. Jing¹, J. Luo², Y. Yi², and H. Zhu³; ¹Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, ²Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, ³Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

Purpose/Objective(s): The aim of this study was to determine the safety and clinical efficacy of Weekly cisplatin/nab-paclitaxel (QW) over tri-weekly (Q3W) as neoadjuvant chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma (LA-ESCC). Materials/

Methods: A retrospective chart review at two institutions of patients who underwent esophagectomy after neoadjuvant chemoradiotherapy with either Weekly cisplatin/nab-paclitaxel or tri-weekly cisplatin/nab-paclitaxel was performed. Demographics as well as staging, pathological complete response, major pathologic response were collected. Univariate analysis between the two groups was performed.
Results: We included 104 and 32 patients in the Q3W and QW groups, respectively. Baseline demographic and clinical characteristics were well balanced between groups. Overall, 53 of 136 patients achieved pCR (38.97 %). The pCR rate was significantly different between the Q3W and QW groups (43.75% vs. 56.25%, p= 0.022). The Q3W group exhibited significantly higher hematologic (leukopenia, p=0.015; neutropenia, p=0.003) of all grades than the QW group. Patients in the Q3W group presented higher incidence of grade = 3 leukopenia and neutropenia than those in the QW group (51.92 % vs. 18.75%, p= 0.002; 38.46 % vs. 15.62 %, p<span>= 0.029). No significant differences in non-hematologic AEs and postoperative complications (all P>0.05). OS and PFS did not significantly differ between groups. The estimated 1-year OS and PFS rates were 92.83%% versus 96.90% and 86.49% versus 88.46% for QW and Q3W groups (P>0.05), respectively.
Conclusion: Compared with tri-weekly cisplatin/nab-paclitaxel, weekly chemotherapy was associated with increased pathologic complete response and superior safety profile for patients with resectable advanced ESCC.